GSK licenses liver disease drug to Italy's Alfasigma

GSK agreed to sell worldwide development and commercialization rights to experimental liver-disease drug linerixibat to Alfasigma for an upfront $300 million. The deal transfers pipeline risk and provides GSK with near-term cash while giving Alfasigma global rights to pursue development/commercialization. No further financial terms or milestone/royalty details were disclosed.

Analysis

GSK agreed to sell worldwide development and commercialization rights to experimental liver-disease drug linerixibat to Alfasigma for an upfront $300 million. The deal transfers pipeline risk and provides GSK with near-term cash while giving Alfasigma global rights to pursue development/commercialization. No further financial terms or milestone/royalty details were disclosed.